Antiretroviral Postexposure Prophylaxis After Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV in the United States: Recommendations from the U.S. Department of Health and Human Services

2003 ◽  
Vol 33 (1) ◽  
pp. 29-36 ◽  
Author(s):  
Sonia Shah

Drug companies' quest for speedy results has led to a boom in trials based in developing countries, where ethical standards may be lax and the impoverished sick abundant. According to the U.S. Department of Health and Human Services Inspector General's office, the number of researchers based outside the United States seeking new drug approvals has increased 16-fold over the last decade. In this article, a 1996 Pfizer trial in Nigeria—the subject of a controversial class-action suit—illustrates the dangers.


PEDIATRICS ◽  
1994 ◽  
Vol 94 (6) ◽  
pp. 952-954
Author(s):  
Martin S. Robinette

The importance of early identification of hearing loss is summarized in the report issued by the United States (US) Department of Health and Human Services,1 entitled "Healthy People 2000." The goal is to reduce the average age at which children with significant hearing impairment are identified to no more than 12 months. The report states: The future of a child born with significant hearing impairment depends to a very large degree on early identification (ie, audiological diagnosis before 12 months of age) followed by immediate and appropriate intervention.


Sign in / Sign up

Export Citation Format

Share Document